Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roche Holding AG Basel American Depositary Shares (OP: RHHBY ) 39.26 +0.45 (+1.16%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Roche Holding AG Basel American Depositary Shares < Previous 1 2 3 4 5 6 7 8 9 ... 27 28 Next > New England Journal of Medicine Publishes Landmark Phase III Results for Genentech’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer October 30, 2024 From Genentech Via Business Wire Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket October 30, 2024 Via Benzinga Biotech Momentum Trades For The Q4 Rally October 29, 2024 The biotech sector made an interim peak in late February followed by an active summer in very choppy trading. Via Talk Markets Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review October 25, 2024 The major indexes were mixed for the week. Via Investor's Business Daily Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition October 23, 2024 Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. Via Benzinga Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales Expectations October 23, 2024 The Swiss drugmaker kept its outlook for the year despite a third-quarter sales miss. Via Investor's Business Daily Can Roche Challenge Lilly and Novo in the Weight Loss Market? October 22, 2024 One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate. Via MarketBeat Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study October 18, 2024 From Genentech Via Business Wire Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up October 18, 2024 The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. Via Investor's Business Daily Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer October 15, 2024 Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance treatment for extensive-stage small-cell lung cancer. Jazz plans to submit a... Via Benzinga Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade October 14, 2024 The analyst is closely watching MariTide, a potential monthly injection to treat obesity. Via Investor's Business Daily Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate October 14, 2024 From Genentech Via Business Wire Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names October 11, 2024 The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. Via Benzinga FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation October 10, 2024 From Genentech Via Business Wire Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday? October 10, 2024 Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in patients... Via Benzinga Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer October 08, 2024 Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set... Via Benzinga Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year October 07, 2024 Scholar Rock's Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy met its primary endpoint, showing statistically significant motor function improvements and favorable outcomes compared... Via Benzinga Exposures Product Safety 2 Artificial Intelligence Stocks That Could Deliver Explosive Gains October 07, 2024 These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead. Via The Motley Fool Topics Artificial Intelligence Exposures Artificial Intelligence Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point? October 06, 2024 Renowned economist Justin Wolfers highlighted this significant shift on social media platform X, stating, "From the Department of Things Really Are Getting Better: The U.S. obesity rate may have... Via Benzinga Week In Review: Regor Sells Two CDK Inhibitors To Genentech For $850 Million October 05, 2024 Regor Pharma, a Shanghai-Boston biotech, sold global rights to Genentech for two early-stage CDK inhibitors aimed at breast cancer. Regor will receive $850 million upfront, a hefty amount for two Phase... Via Talk Markets As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer October 04, 2024 Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. Via Investor's Business Daily 3 Top Stocks That Could Still Rocket Higher in 2024 October 04, 2024 Upcoming Food and Drug Administration decisions could push these stocks through the roof. Via The Motley Fool Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential September 30, 2024 Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales. The company aims to launch 20 transformative drugs by 2030 while cutting... Via Benzinga Positive Phase III Results for Genentech’s Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis September 26, 2024 From Genentech Via Business Wire Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points September 21, 2024 NFLX is among four stocks on the list that's actionable now. Via Investor's Business Daily Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows September 19, 2024 Roche's phase 3 CENTERSTONE study shows Xofluza (baloxavir marboxil) significantly reduces influenza transmission in households, marking a global first for an antiviral. Via Benzinga 2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? September 19, 2024 Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. Via Investor's Business Daily Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses September 19, 2024 From Genentech Via Business Wire 1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc) September 17, 2024 Telemedicine once seemed like it was going to revolutionize healthcare. Via The Motley Fool Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections September 16, 2024 The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first twice-a-year subcutaneous injection option for both forms of the disease. Via Benzinga Exposures Product Safety < Previous 1 2 3 4 5 6 7 8 9 ... 27 28 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
